80%Confidence
0Views
FDASource
2026-03-28Date
Summary
Rising Pharma's Temozolomide stability test failure suggests potential degradation issues in oncology medications, which could impact treatment efficacy for brain tumor patients. This may lead to increased regulatory oversight of stability testing protocols across the generic pharmaceutical industry.
Actionable: Healthcare providers should review their temozolomide inventory and consider alternative suppliers until Rising Pharma demonstrates improved quality control.
AI Confidence: 80%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now